Entia is an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to the fields of food science biotechnology and Nutrigenomics. The Company identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty and agriculture.
For more information, please visit our web sites at www.entiabio.com or contact:
Devin AndresChief Operating OfficerEntia Biosciences, Inc.13565 SW Tualatin-Sherwood Rd Sherwood, OR, 97140Phone: 503-334-3575 Email: firstname.lastname@example.org
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2012 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.Bibliography: Burmer, G. (2012). TNCS001A-1/SLC22A4. Entia Biosciences. Grigat, S. et al. (2007). Probing the Substrate Specificity of the Ergothioneine Transporter with Methimazole, Hercynine,and Organic Cations. Biochem. Pharmacol., 74, 309-316. Grundemann, D. et al. (2005). Discovery of the Ergothioneine Transporter. Proc. Natl. Acad. Science (PNAS), 102(14), 5256-5261. Lin, MT. & Beal, MF . (2006). Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases. Nature, 443, 787-795. Mydel, P. et al. (2006). Roles of the Host Oxidative Immune Response and Bacterial Antioxidant Rubrerythrin During Porphyromonas gingivalis Infection. PloS. Pathog., 2(7), 71-76. Paul, B. & Snyder, S., (2009). The Unusual Amino Acid L-Ergothioneine is a Physiologic Cytoprotectant. Cell Death & Differentiation, pp. 1-7. Reddy, P. (2009). The Role of mitochondria in Neurodegenerative Diseases: Mitochondria as a Therapeutic Target in Alzheimer's Disease. CNS Spectr., 14(8), 8-18. Salt, HB (1931). The Ergothioneine Content of the Blood in Health and Disease. Biochem J., 25(5):1712-1719
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts